Clinical Trial Update: Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) [Phase 3]

View source ↗

Summary

A Phase 3 trial (DESTINY-Ovarian01) compares trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance in HER2-expressing ovari…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)
• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Ovarian Cancer | Phase 3 | Status: RECRUITING